AI-assisted, human-published
11/18/2025 /Funding Events
VahatiCor Secures Funding to Advance Medical Technology for Coronary Microvascular Dysfunction
VahatiCor, a T45 Labs portfolio company, receives funding to advance innovative medical technology for Coronary Microvascular Dysfunction (CMD). The capital will be used for SERRA-I enrollment, engineering development, and planning for pivotal trials and regulatory interactions.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com